AEterna Zentaris's lead drug fails second Phase III trial in BPH
16 December 2009
Katie McQue
Please Login to read the full article.
16 December 2009
Katie McQue
katie.mcque@informa.com
The future of AEterna Zentaris's lead drug candidate cetrorelix has been left in doubt after it failed to meet the primary endpoint of its second Phase III trial in benign prostate hyperplasia (BPH).
"We are obviously disappointed by the failure of study Z-036 to reach its efficacy endpoint,"...
Please Login to read the full article.
RELATED CONTENT
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
